20 citations
,
November 2020 in “Stem Cell Research & Therapy” Enhanced stem cells from the placenta can help treat Graves' eye disease by stopping fat cell growth.
September 2020 in “Research Square (Research Square)” Enhanced stem cells from the placenta can reduce fat buildup in eye tissue for Graves' disease.
August 2020 in “Research Square (Research Square)” The study investigated the effects of PRL-1-overexpressing placenta-derived mesenchymal stem cells (PD-MSCs PRL-1) on adipogenesis in orbital fibroblasts (OFs) from patients with Graves’ ophthalmopathy (GO). The research found that PD-MSCs PRL-1 significantly reduced lipid accumulation and decreased the expression of adipogenic markers in OFs compared to naïve cells. This effect was linked to the secretion of insulin-like growth factor-binding proteins (IGFBPs) by PD-MSCs PRL-1, which downregulated the PI3K/AKT/mTOR signaling pathway and upregulated phosphorylated FAK through integrin interactions. These findings suggested that functionally enhanced PD-MSCs could offer a novel therapeutic approach for treating degenerative diseases like GO.
488 citations
,
July 2021 in “Cell” Fibroblasts are crucial for tissue repair and inflammation, and understanding them can help treat fibrotic diseases.